Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTTR1147A vs Vedolizumab in Moderate to Severe Ulcerative Colitis
NCT03558152Phase 2Completed
- Sponsor
- Genentech
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 16
01
Overview
A Phase 2 trial of efmarodocokin alfa in ulcerative colitis (UC), sponsored by Genentech. Started Oct 2018; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03558152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558152.